Primary Care Services
Coordinating primary care services, especially for patients diagnosed with critical medical conditions. Neuronanomed ALS Zentrum is dedicated to providing individuals and families living with motor neuron diseases, in particular Amyotrophic Lateral Sclerosis (ALS), the opportunity to receive comprehensive care, therapy, education, awareness programs, clinical consultation and support to achieve their highest level of wellness. The center provides advanced compensatory strategies and multidisciplinary care for ALS patients that includes respiratory, physical, occupational and speech therapy to maintain strength and utility of the affected motor functions to help patients live independently for as long as possible. For information contact our International consultant: BrünstlMedizin Healthcare: info@bruenstlmedizin.de
How might COVID-19 impact ALS patients?
Anyone with ALS is at very high risk to get COVID-19 and have comlications. Most at risk are those with any respiratory muscle weakness and/or bulbar involvement. Although ALS patients in general have a good immune system. the most worrisome thing is the lack of a strong cough to clear away the secretions that may accompany the viral infection.Those secretions may stay in the lung and leadto pneumonia. So make sure you are avoiding cintacts as much as feasible (physical distancing ) and if you have been prescribed a cough assist and /or breath stacking device. use them religiously at least twice daily.
Precuaions forALS patients,caregiver,family members:
Family members and caregivers should take appropriate precautions to avoid bringing COVID-19 home.
They should constantly monitor patients and stock medicines and other necessary supplies that can last for several weeks.
ALS Updates
BrünstlMedizin Amyotrophe Lateralsklerose Forschung
Tag Archives: ALS
Science daily ALS
European Network for the Cure of ALS
SECARS-Mikroskopie – ein Fenster in die Welt der Moleküle
Gene therapy: can neural stem cells deliver?
Early promise for the treatment of ALS
Neuralstem reports top line data from NSI-566 Phase II trial for treatment of ALS
New insight into the occurrence of ALS
Antioxidant OXR1 protects neurons and extends survival for ALS
ALS – a model of corticofugal axonal spread
ACE-inhibitors associated with lower risk for ALS above certain dose over time
Help us create a world without ALS
BrünstlMedizin-Neuronanomed ALS Zentrum Consultants
– Dr. Albert C. Ludolph, Ärztlicher Direktor RKU -Universitäts-Rehabilitationskliniken,ULM,Deutschland
– Dr. Francesco Roselli
Abteilung Neurologie, Universität ULM, Deutschland
– Dr. Markus Weber
Zentrumsleiter Muskelzentrum/ALS Clinic, Switzerland
– Dr. Deniz Yilmazer-Hanke
Zentrun für Biomedizinsche Forschung, Deutschland
– Dr Lina Machtoub
Universitätsklinik für Radiologie, Innsbruck Österreich
– Dr. Bernhard Schuknecht
Medizinischches Inst. Radiologis, Zurich, Switzerland
– Dr. Marco Pagani
Institute for Cognitive Sciences & Technologies, Italy